These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27373969)

  • 1. Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications.
    de Bruin RCG; Lougheed SM; van der Kruk L; Stam AG; Hooijberg E; Roovers RC; van Bergen En Henegouwen PMP; Verheul HMW; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2016 Aug; 169():128-138. PubMed ID: 27373969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
    de Weerdt I; Lameris R; Ruben JM; de Boer R; Kloosterman J; King LA; Levin MD; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
    Clin Cancer Res; 2021 Mar; 27(6):1744-1755. PubMed ID: 33451981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Vgamma9Vdelta2 T cells: from signals to functions.
    Nedellec S; Bonneville M; Scotet E
    Semin Immunol; 2010 Aug; 22(4):199-206. PubMed ID: 20447835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
    de Bruin RC; Stam AG; Vangone A; van Bergen En Henegouwen PM; Verheul HM; Sebestyén Z; Kuball J; Bonvin AM; de Gruijl TD; van der Vliet HJ
    J Immunol; 2017 Jan; 198(1):308-317. PubMed ID: 27895170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire.
    Dimova T; Brouwer M; Gosselin F; Tassignon J; Leo O; Donner C; Marchant A; Vermijlen D
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):E556-65. PubMed ID: 25617367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An abnormal phenotype of lung Vγ9Vδ2 T cells impairs their responsiveness in tuberculosis patients.
    El Daker S; Sacchi A; Montesano C; Altieri AM; Galluccio G; Colizzi V; Martini F; Martino A
    Cell Immunol; 2013 Apr; 282(2):106-12. PubMed ID: 23770719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma.
    Sicard H; Al Saati T; Delsol G; Fournié JJ
    Mol Med; 2001 Oct; 7(10):711-22. PubMed ID: 11713370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
    de Bruin RCG; Veluchamy JP; Lougheed SM; Schneiders FL; Lopez-Lastra S; Lameris R; Stam AG; Sebestyen Z; Kuball J; Molthoff CFM; Hooijberg E; Roovers RC; Santo JPD; van Bergen En Henegouwen PMP; Verheul HMW; de Gruijl TD; van der Vliet HJ
    Oncoimmunology; 2017; 7(1):e1375641. PubMed ID: 29296532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells.
    Gomes AQ; Correia DV; Grosso AR; Lança T; Ferreira C; Lacerda JF; Barata JT; Silva MG; Silva-Santos B
    Haematologica; 2010 Aug; 95(8):1397-404. PubMed ID: 20220060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
    Bonneville M; Scotet E
    Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells.
    Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G
    Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
    Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
    J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies.
    Hussack G; Arbabi-Ghahroudi M; Mackenzie CR; Tanha J
    Methods Mol Biol; 2012; 911():211-39. PubMed ID: 22886255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.